| Name | Title | Contact Details |
|---|
Convenience Kits Intl. is a Lynbrook, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WithMe Health replaces an employer`s pharmacy benefit manager (PBM) with a personalized medication guidance solution that greatly improves on and expands the scope of services available in the market today. Our modern technology and rich datasets allow consistent application of proven science to create individualized medication experiences for employees and their families that are proactive, adaptive, convenient and engaging. With an innovative, outcomes-oriented business model that aligns interests across the pharmaceutical value chain, WithMe Health optimizes health outcomes and value while substantially reducing costs for employers.
Beacon Health is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sensely`s avatar and chatbot-based platforms assist insurance plan members and patients with the insurance services and healthcare resources they need, when they need it.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.